INNA SOMINSKY M.D.
Prescription History 1649463522
Internal Medicine - Hematology & Oncology in Brooklyn, NY
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for INNA SOMINSKY M.D., an active Hematology & Oncology specialist practicing in Brooklyn, NY. Our medical registry currently tracks 10 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 179 documented patient claims. Among these therapy options, the most frequently utilized medication is Hydroxyurea, which accounts for 42 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2023)Rx (2023) | Avg Cost per FillCost / Fill | Vs. Other NY PrescribersVs. NY Avg |
|---|---|---|---|
| Hydroxyurea | 42 | $21.45▼ below NY avg | ≈ Typical |
About Hydroxyurea: This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Show more ▾ Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas). An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. In 2023, this provider wrote 42 Medicare prescriptions for Hydroxyurea, about 1.2 times the volume of the typical New York prescriber of this medication (34). Medicare paid an average of $21.45 per fill, versus $32.36 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 58 30-Day Fills standardized to 30-day supplies 1,740 Days of Medication total across all patients in 2023 | |||
| Lenalidomide | 21 | $7,901.06▼ below NY avg | ≈ Typical |
About Lenalidomide: Lenalidomide is used to treat various types of cancers. Show more ▾ It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication. A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA. In 2023, this provider wrote 21 Medicare prescriptions for Lenalidomide, about the same volume as the typical New York prescriber of this medication (20). Medicare paid an average of $7,901.06 per fill, versus $14,905.13 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 21 30-Day Fills standardized to 30-day supplies 581 Days of Medication total across all patients in 2023 | |||
| JakafiRuxolitinib Phosphate | 18 | $17,546.26 | ▼ Less than typical |
About Jakafi: This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). Show more ▾ It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as kinase inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. Ruxolitinib is also used to treat a certain problem that may occur after certain stem cell or bone marrow transplants (graft versus host disease). It works by weakening your body's defense system (immune system). In 2023, this provider wrote 18 Medicare prescriptions for Jakafi, about 62% of the volume of the typical New York prescriber of this medication (29). Medicare paid an average of $17,546.26 per fill, versus $16,369.55 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 18 30-Day Fills standardized to 30-day supplies 540 Days of Medication total across all patients in 2023 | |||
| Allopurinol | 16 | $7.06▼ below NY avg | ▼ Less than typical |
About Allopurinol: Allopurinol is used to treat gout and certain types of kidney stones. Show more ▾ It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems. A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms. In 2023, this provider wrote 16 Medicare prescriptions for Allopurinol, about a third of the volume of the typical New York prescriber of this medication (44). Medicare paid an average of $7.06 per fill, versus $14.64 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 16 30-Day Fills standardized to 30-day supplies 480 Days of Medication total across all patients in 2023 | |||
| Imatinib Mesylate | 16 | $4,562.78 | ▼ Less than typical |
About Imatinib Mesylate: This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). Show more ▾ It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome). A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors. In 2023, this provider wrote 16 Medicare prescriptions for Imatinib Mesylate, about 73% of the volume of the typical New York prescriber of this medication (22). Medicare paid an average of $4,562.78 per fill, versus $3,439.12 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 16 30-Day Fills standardized to 30-day supplies 480 Days of Medication total across all patients in 2023 | |||
| Letrozole | 15 | $15.66▼ below NY avg | ▼ Less than typical |
About Letrozole: This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Show more ▾ Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women. In 2023, this provider wrote 15 Medicare prescriptions for Letrozole, about a third of the volume of the typical New York prescriber of this medication (48). Medicare paid an average of $15.66 per fill, versus $29.75 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 31 30-Day Fills standardized to 30-day supplies 930 Days of Medication total across all patients in 2023 | |||
| Prednisone | 14 | $17.64 | ▼ Less than typical |
About Prednisone: Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Show more ▾ Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions. A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. In 2023, this provider wrote 14 Medicare prescriptions for Prednisone, about a third of the volume of the typical New York prescriber of this medication (44). Medicare paid an average of $17.64 per fill, versus $6.20 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 14 30-Day Fills standardized to 30-day supplies 395 Days of Medication total across all patients in 2023 | |||
| Anastrozole | 13 | $13.24▼ below NY avg | ▼ Less than typical |
About Anastrozole: Anastrozole is used to treat breast cancer in women after menopause. Show more ▾ Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women. In 2023, this provider wrote 13 Medicare prescriptions for Anastrozole, about a quarter of the volume of the typical New York prescriber of this medication (64). Medicare paid an average of $13.24 per fill, versus $28.63 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 19 30-Day Fills standardized to 30-day supplies 570 Days of Medication total across all patients in 2023 | |||
| NucalaMepolizumab | 13 | $4,256.91▼ below NY avg | ▼ Less than typical |
About Nucala: This medication is used along with other medications to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Show more ▾ Controlling symptoms of asthma helps you do your normal activities and decreases time lost from work or school. Mepolizumab is also used to treat certain other immune system disorders (chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome). This medication works by decreasing a certain type of white blood cell (eosinophils). This effect helps reduce swelling (inflammation) of the airways to make breathing easier. It may also help reduce the size of nasal polyps, and lessen symptoms such as runny/stuffy nose, mucus in the throat, loss of smell, facial pain, and tiredness. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack occurs, use your quick-relief inhaler as prescribed. In 2023, this provider wrote 13 Medicare prescriptions for Nucala, about half the volume of the typical New York prescriber of this medication (24). Medicare paid an average of $4,256.91 per fill, versus $4,259.69 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 13 30-Day Fills standardized to 30-day supplies 364 Days of Medication total across all patients in 2023 | |||
| CalquenceAcalabrutinib Maleate | 11 | $16,244.37 | ▼ Less than typical |
About Calquence: This medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL). Show more ▾ Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors. In 2023, this provider wrote 11 Medicare prescriptions for Calquence, about a third of the volume of the typical New York prescriber of this medication (32). Medicare paid an average of $16,244.37 per fill, versus $13,727.57 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 11 30-Day Fills standardized to 30-day supplies 330 Days of Medication total across all patients in 2023 | |||
About this data. The prescription history for INNA SOMINSKY M.D. is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2023, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Hematology & Oncology prescribing approach at this Brooklyn, NY practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average volume among NY prescribers of the same medication. Always confirm current medications and costs directly with the provider and your plan.
